The Evolving Second-Line Treatment Landscape in HR+, HER2- Metastatic Breast Cancer
home / case-based-digest / the-evolving-second-line-treatment-landscape-in-hr-her2-metastatic-breast-cancer
As part of its Case-Based Digest series, Oncology Nursing News spoke with experts about second-line treatment of HR-positive, HER2-negative metastatic breast cancer.
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
September 20th 2024During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in particular with the use of elacestrant, in HR-positive, HER2-negative metastatic breast cancer.
